The scientist’s investigation covers issues in Internal medicine, Endocrinology, Albuminuria, Diabetic nephropathy and Diabetes mellitus. His Internal medicine research is multidisciplinary, relying on both Type 1 diabetes and Nephropathy. While the research belongs to areas of Endocrinology, he spends his time largely on the problem of Urology, intersecting his research to questions surrounding Angiotensin II and Irbesartan.
His Albuminuria study combines topics in areas such as Creatinine, Microalbuminuria, Type 2 diabetes and Captopril. His study in Diabetic nephropathy is interdisciplinary in nature, drawing from both Odds ratio and Incidence. His biological study spans a wide range of topics, including Gastroenterology, Surgery, Immunopathology and Risk factor.
Hans-Henrik Parving mainly focuses on Internal medicine, Endocrinology, Diabetes mellitus, Diabetic nephropathy and Albuminuria. His Internal medicine study typically links adjacent topics like Nephropathy. As part of the same scientific family, Hans-Henrik Parving usually focuses on Endocrinology, concentrating on Cardiology and intersecting with Left ventricular hypertrophy.
The study incorporates disciplines such as Gastroenterology, Surgery and Risk factor in addition to Diabetes mellitus. In Diabetic nephropathy, Hans-Henrik Parving works on issues like Angiotensin-converting enzyme, which are connected to Angiotensin II receptor type 1. His Albuminuria study combines topics from a wide range of disciplines, such as Excretion and Hazard ratio.
Hans-Henrik Parving mainly investigates Internal medicine, Endocrinology, Diabetes mellitus, Albuminuria and Diabetic nephropathy. His studies deal with areas such as Type 1 diabetes and Type 2 diabetes as well as Internal medicine. In the field of Endocrinology, his study on Nephropathy, Blood pressure, Vitamin D and neurology and Angiotensin II overlaps with subjects such as Crossover study.
The Diabetes mellitus study which covers Gastroenterology that intersects with Proportional hazards model. Hans-Henrik Parving focuses mostly in the field of Albuminuria, narrowing it down to matters related to Urology and, in some cases, Aliskiren and Losartan. His Diabetic nephropathy study frequently links to related topics such as Pathogenesis.
His scientific interests lie mostly in Internal medicine, Albuminuria, Endocrinology, Renal function and Diabetes mellitus. His work deals with themes such as Type 1 diabetes and Type 2 diabetes, which intersect with Internal medicine. His work in Albuminuria tackles topics such as Microalbuminuria which are related to areas like Proteinuria, Prospective cohort study and Uric acid.
Endocrinology is often connected to Urology in his work. His study focuses on the intersection of Diabetes mellitus and fields such as Gastroenterology with connections in the field of vitamin D deficiency, Vitamin D and neurology, Endothelium, Endothelial dysfunction and Excretion. His Kidney disease study deals with Nephropathy intersecting with Ambulatory blood pressure, Observational study and Follow up studies.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
Hans-Henrik Parving;Hendrik Lehnert;Jens Bröchner-Mortensen;Ramon Gomis.
The New England Journal of Medicine (2001)
Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
Peter Gæde;Henrik Lund-Andersen;Hans-Henrik Parving;Oluf Pedersen.
The New England Journal of Medicine (2008)
Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy
Hans-Henrik Parving;Frederik Persson;Julia B. Lewis;Edmund J. Lewis.
The New England Journal of Medicine (2008)
Nephropathy in diabetes.
Mark E Molitch;Ralph A DeFronzo;Marion J Franz;William F Keane.
Diabetes Care (2004)
Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study
Peter Gaede;Pernille Vedel;Hans Henrik Parving;Oluf Pedersen.
The Lancet (1999)
EARLY AGGRESSIVE ANTIHYPERTENSIVE TREATMENT REDUCES RATE OF DECLINE IN KIDNEY FUNCTION IN DIABETIC NEPHROPATHY
Hans-Henrik Parving;UllaM Smidt;AllanR Andersen;PerAa Svendsen.
The Lancet (1983)
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL
Dick De Zeeuw;Giuseppe Remuzzi;Hans Henrik Parving;William F. Keane.
Kidney International (2004)
Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: Progressive, interrelated, and independently associated with risk of death
Coen D.A. Stehouwer;Mari-Anne Gall;Jos W.R. Twisk;Elisabeth Knudsen.
Prevention of diabetic renal disease with special reference to microalbuminuria
C. E. Mogensen;W. F. Keane;P. H. Bennett;G. E. Striker.
The Lancet (1995)
Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion
H H Parving;B Oxenbøll;P A Svendsen;J S Christiansen.
European Journal of Endocrinology (1982)
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking h-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: